Intermittent drug therapy for profoundly mentally retarded persons by Millichamp, Catherine Jane
INTERMITTENT DRUG THERAPY FOR 
PROFOUNDLY MENTALLY RETARDED PERSONS 
C. JANE MILLICHAMP 
A thesis submitted in partial fulfill~ent 
of the requirements for the degree of 
MASTER OF ARTS 
IN PSYCHOLOGY 





Prevalence of Drug Usage 
Pharmacotherapy with the Mentally Retarded 
Reduction of Drug Use 
METHOD 
Subjects and Setting 
Response Definitions 
















Intermittent Drug Therapy: Overall Behavioral Effects 23 
Intermittent Drug Therapy: Behavioral Effects for 26 
each Subject. 





Sincere thanks to my supervisor, Dr Nirbhay Singh, for his kindness, 
support and encouragement throughout. 
I would like to express my appreciation to Dr Jim Marshall, Medical 
Superintendent of Templeton Hospital, and his staff for facilitating this 
study. 
Many thanks also to the four observers, Engel Scholten, the nursing 
staff and the residents of Cedar Villa, whose help and cooperation are 
greatly appreciated. 
I am very grateful to Lyonne Dalley, Jane Guillen, and Robin Phillips 
for their meticulous practical assistance in the preparation of this 
thesis. 
Finally, I am very grateful to my family and friends, who have 
supported and encouraged me during the course of this thesis. 
1 
ABSTRACT 
Many institutionalized mentally retarded persons currently receive 
maintenance medication for behavior problems. Prolonged use of certain 
antipsychotic medication can produce adverse side-effects. A double-
blind, placebo-controlled study was conducted to assess the effects of 
intermittent drug therapy. Six profoundly retarded males all of whom 
had received maintenance antipsychotic medication for more than three 
years, participated in the study. Formal observations were made across 
a broad spectrum of subject behaviors during .baseline and four sub-
sequent phases of reduced drug dosage. A multiple baseline across 
subjects design was utilized for this eight-month investigation. No 
clinically significant effects were found when baseline and subsequent 
phases were compared. The results suggested that maintenance medication 
of institutionalized profoundly retarded residents may be reduced 
substantially without concomitant changes in overall drug. effects. 
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Mentally retarded persons are frequently distinguished from the general 
population by their diverse range of learning problems, involving both 
behavioral deficits and excesses. Their maladaptive behaviors are of 
considerable concern to institutional staff and a great deal of time, 
effort and money is expended in attempts to reduce such behaviors. Be-
havioral problems are also troublesome for parents of mentally retarded 
persons and may often lead to institutionalization of the mentally retarded. 
Since ~aladaptive behaviors represent a highly prevalent and significant 
problem, it is crucial that parents and institutional staff have effective 
means of treating them. Effective treatment procedures are advantageous 
for practical, ethical, legal and economical reasons. 
Currently, there are a number of ways in which institutional staff 
deal with the behavior problems of mentally retarded persons. Often 
environmental variables are manipulated in order to suppress behavioral 
excesses such as aggressive/destructive and self-injurious behaviors. 
Usually, either a staff member or a mechanical device (e.g., straitjacket) 
physically restricts the person and prevents the continued occurrence of 
the maladaptive behavior. However, restraint procedures can be problematic 
for both ethical (e.g., long-term use of mechanical restraints) and 
practical reasons (e.g., with physically aggressive residents). 
Isolation is another technique often employed by institutional staff 
to deal with behavior problems. Although purported to be useful, ·this 
procedure may not be effective in a number of situations. Few, if any, 
structured behavior modification programs are implemented in many 
institutions for the mentally retarded. Although some techniques, such as 
verbal reprimand, are frequently but inconsistently employed, these appear 
to be largely ineffective. By far, the most common method of dealing with 
the behavior problems in institutionalized mentally retarded persons is via 
pharmacological intervention. 
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Prevalence of Drug Usage 
A number of surveys have examined the incidence of psychotropic 
drug prescription among the institutionalized mentally retarded. In 
general terms, these surveys indicate that between 40% to 50% of mentally 
retarded residents receive psychotropic medication prescribed specific-
ally for behavior problems. Table 1 provides a detailed description of 
prevalence studies. 
Insert Table 1 about here 
The three most commonly used psychotropic drugs are thioridazine (Mellaril), 
chlorpromazine (Largactil, Thorazine), and haloperidol (Haldol, Serenace). 
(DiMascio, Note l; Lipman, 1970; Sprague, 1977; Pulman, Pook & Singh, 
1979; Sewell & Werry, 1976; Tu & Smith, 1979). If, due to their 
recognised significant impact on behavior and cognition, the anticonvulsants 
are added to the psychotropic prevalence figure, the total prevalence of 
psychoactive drugs (i.e., any agents causing cognitive, behavioral or 
emotional changes) is between 51% to 68%. 
Davis, Cullari and Breuning (1982) reported similar figures for 3,750 
mentally retarded people in community foster homes. Fifty-eight percent 
of these individuals received an antipsychotic drug, with the most commonly 
used being thioridazine. Seventy-four percent of individuals received 
psychoactive medication. The only other study which investigated drug 
prevalence in the community was a survey by Gadow (1978). Gadow (1978) 
reported that 18% of his subjects received psychotropic or antiepileptic 
drugs. Further information concerning drug prevalence with the mentally 
retarded can be found in Aman (1983); Aman and Singh (in press); 
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PREVALENCE OF DRUG TREATMENT IN THE MENTALLY RETARDED 
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Host coounon drugs prescribed 
thioridazine, chlorpromazine, trifluo-
perazine, diazepam, chlordiazepoxide 
phenobarbitone, haloperidol, chlor-
promazine, phenytoin, thioridazine 
Not reported 
thioridazine, chlorpromazine, 
methotrimeprazine, ni trazepam 
thioridazine, phenytoin, phenobarbital, 
diazepam, primadone, mesoridazine 
phenobarbital, phenytoin, diazepam 
(usually as an anticonvulsant), chlor-
promazine, thioridazine, haloperidol 
phenytoin, diazepam, carbamazepine, 
trimeprazine, haloperidol, phenobarbi tone 
promethazine 
phenytoin, phenobarbital, thioridazine, 
hydroxyzine, primadone 
thioridazine, chlorpromazine, 
mesoridazine, diazepam, thioxanthene 
chloral hydrate, carbamazepine, 
thioridazine, • diazepam, haloperidol, 
phenytoin, sodium Valproate 
phenytoin, phenobarbital, methylphenidate, 
primadone, thioridazine, diazepam 
thior idazine, phenytoin, phenobarbital, 
chlorpromazine, diazepam, haloperidol 
Note: Since there is overlap (some patients received both psychotropic and anticonvulsant drugs}, the two component percentages 
will not necessarily equal the total percentage, 
This figure may represent an overestimate of drug incidence since the survey asked how many patients had been, or were 
currently being, treated with psychotropic medication. 
From: Aman & Singh (in press}, 
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PHARMACOTHERAPY WITH THE MENTALLY RETARDED 
Thirty years ago, scarce use was made of drugs to modify behavior. 
However, following the introduction of chlorpromazine in the l950's, the 
development and prescription of psychotropic drugs became widespread. 
With few exceptions, drug prescription trends in mental retardation have 
paralleled those in adult psychiatry, with drugs being prescribed to the 
mentally retarded shortly after their administration to the mentally ill. 
Currently, a wide variety of psychotropic drugs are available for admin-
istration to the mentally retarded. Of these, only the antipsychotics 
are of direct relevance to this study. 
Antipsychotics 
Antipsychotics are the most prescribed drugs with the mentally 
retarded. Surveys have consistently indicated that 40% to 50% of the 
institutionalized mentally retarded receive an antipsychotic drug (e.g., 
Lipman, 1970; Sprague, 1977). The surveys also show that antipsychotics 
are often used for long periods of time and in doses exceeding those 
recommended by the drug's manufacturer. Antipsychotics consist of four 
main classes: phenothiazines, butyrophenones, thioxanthenes, and rauwqlfia 
alkaloids. By far the most frequently prescribed of the antipsychotics 
are chlorpromazine, thioridazine (both phenothiazines) and haloperidol (a 
butyrophenone) and these are usually prescribed to treat aggression, 
destructiveness, self-injury, se.lf-stimulation and hyperactivity. 
Chlorpromazine: Chlorpromazine (Largactil) is·one of the oldest and 
most used psychotropic drugs with the mentally retarded. Early studies 
which were poorly controlled (see reviews by Lipman, DiMascio, Reatig & 
Kirson, 1978; freeman, 1970; Sprague & Werry, 1971) reported 
that chlorpromazine reduced problem behaviors of the mentally retarded. 
However, more recent and methodologically sound investigations suggest that 
chlorpromazine is not beneficial and may in fact have a negative effect on 
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adaptive behaviors (Marholin, Touchette & Stewart, 1979; Moore, 1960). 
However, no definitive conclusions can be drawn since there are few 
well~controlled studies of the effects of chlorpromazine on the behavior 
of mentally retarded persons. 
Thioridazine (Mellaril): In a review of the effects of thioridazine 
in childhood disorders (including mental retardation), Aman and Singh 
(1980) found most studies to be methodologically inadequate or to make 
only global evaluations of efficacy. The few well-controlled studies 
which have been conducted indicate that thioridazine may imp~ove hyper-
activity, aggression, eating behavior and stereotypy, (e.g., Alexandris & 
Lundell, 1968; Breuning, 1982; Davis, Sprague & Werry, 1969; Heistad 
& Zimmerman, 1979; Singh & Aman, 1981. Moreover, two studies (Breuning, 
1982; Singh & Aman, 1981) have found that lower doses of thioridazine 
are as beneficial as higher doses. Of two operant-based investigations, 
one found no significant drug-related changes (Davis, 1971) and the other 
suggested that thioridazine impaired discrimination learning (Wysocki, 
Fuqua, Davis & Breuning, 1981). In addition, the few studies investigating 
cognitive effects of thioridazine suggest that this drug may impair learning 
performance (see Aman, in press). 
In summary, while the quality of thioridazine studies has varied, 
they generally indicate that this drug is useful in altering some mal-
adaptive behaviors. However, there are some disadvantages associated 
with the drug, e.g., cognitive impairment. 
Haloperidol (Haldol, Serenace): Haloperidol is often prescribed for 
hyperactivity, aggression and impulsive behaviors of the mentally retarded.· 
Few studies have investigated the effects of haloperidol on the behavior 
of mentally retarded persons and, as with the phenothiazines, the majority 
of investigations are methodologically deficient. Two poorly controlled 
studies (Grabowski, 1973a; 1973b) indicated that haloperidol improved the 
behavior of children and adolescents. In a placebo-controlled invest-
igation, Burk and Menolascino (1968) evaluated its effects in global 
terms and found that haloperidol produced significant improvement in 
the behavior of the subjects. Finally, Claghorn (1972), Ucer and 
Kreger (1969) and Le Vann (1970) reported haloperidol to be superior 
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to the phenothiazines and potentially beneficial for reducing hyperactive, 
aggre~sive and self-stimulatory behavior. However, further research is 
required before firm conclusions can be drawn. 
Recent Studie~ on Antipsychotics 
The findings concerning the effects of antipsychotics on the mentally 
retarded are quite ambiguous. Recent, methodologically sound studies of 
antipsychotics are briefly reviewed to present a more meaningful picture. 
Researchers have evaluated antipsychotics by measuring their effects 
on different variables, ,most commonly on their ability to reduce behavioral 
problems, e.g., aggression, stereotypy. For example, four studies found 
antipsychotic drugs to be effective in reducing stereotyped behaviors, 
(Davis, Sprague & Werry, 1969; Hollis, 1968; Singh & Aman, 1981; Zimmerman 
& Heistad, 1982). However, other well-controlled studies (Breuning, 
Ferguson, Davidson & Poling, in press; Breuning, O'Neill & ferguson, 1980; 
Marholin et al., ,1979; McConahey, Thompson & Zimmerman, 1977) have shown 
adverse or no drug effect on clinical measures other than stereotypy. 
While further research is essential, in general terms it can be said that 
antipsychotics may be effective in reducing stereotypic behavior in some 
mentally retarded persons but their effects on other antisocial behaviors 
are unclear. 
A number of researchers have studied the effects of antipsychotic 
medication on cognitive performance (see Aman, in press). Of the three 
studies indicating significant changes in learning, two showed improvement 
(Alexandris & Lundell, 1968; Bair & He'rold, 1955) and one showed worsening 
(Moore, 1960). Unfortunately, these studies were methodologically deficient 
and their findings need to be replicated in better controlled investigations. 
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A more rigorous study (Wysocki, Fuqua, Davis & Breuning, 1981) suggested 
that thioridazine impeded learning for four retarded adults performing a 
matching-to-sample task. Further, a series of studies by Breuning, 
O'Neill & Ferguson (1980) has shown that the antipsychotics interfere 
with token economy programs. Recent studies (Breuning & Davidson, 1981; 
Breuning, Ferguson, Davidson & Poling, in press) have sh~wn that even 
with very low doses, the antipsychotics may impair the subject's responding 
to external reinforcement. While these studies suggest that the a,nti-
psychotics impair learning performance, Aman (in press) has point~d out 
several flaws in these investigations, making further research necessary. 
Side Effects of Antipsychotics 
The antipsychotics are also known to have a number of side effects 
which can be both enduring and severe. Short-term side effects such as 
mild drowsiness, apathy, lethargy, dry mouth, blurred vision, urinary 
retention, abdominal pain and constipation are quite common. Other short-
term effects include akathesia (distinguished by motor restlessness), 
dystonic reactions (abrupt spasms of the head, neck and upper back), and 
Parkinsonian reactions (characterized by body rigidity, masklike expression, 
and shuffling gait). Withdrawal dyskinesias are another side effect 
following abrupt discontinuation. 
Long-term side effects include weight gain, corneal edema, and 
persistent tardive dyskinesias. The latter are distinguished from with-
drawal dyskinesias in that withdrawal dyskinesias occur only for 12-16 
weeks after drug discontinuation. Tardive dyskinesias may be irreversible 
and no effective treatment is currently available. Although current 
prevalence figures are highly variable and range from 1% to 41% of 
subjects treated with antipsychotics (Shepherd & Watt, 1977), it appears 
that mentally retarded persons have a high risk of developing this disorder 
(Gualtieri & Hawk, 1980). 
Methodology 
It is unfortunate that a large majority of drug studies with the 
mentally retarded are of abysmal quality (see Sprague & Werry, 1971). 
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This lack of methodological rigor was even more prevalent prior to the 
1970's when most drug studies employed group designs, with few studies 
incorporating some of the more important requirements of placebo-controlled, 
double-blind, crossover designs. 'In recent years, a wide range of 
experimental designs has been developed, including the refinement of 
single-subject methology. In addition, Sprague and Werry's (1971) 
proposal of six minimal criteria for well-controlled drug studies has had 
some impact on the research in this area. The criteria include (1) placebo 
control, (2) random assignment to drug groups, (3) "blind" evaluation of 
drug effects, (4) standardized dosages, (5) standardized evaluations, and 
(6) appropriate statistical analysis. Aman & Singh (1980) added a further 
criterion, that trials should be free of other confounding drugs. 
In previous research, all the above principles were frequently 
ignored, the most common violation being the inappropriate use of 
statistics. However, it appears that the calibre of drug studies with the 
mentally re_tarded has improved over recent years. For a more comprehensive 
discussion of the methodology of psychopharmacological studies, see Aman 
(1983), Aman and Singh (in press), Breuning, Davis and Poling (1982), Hersen 
and Barlow (1976), Liberman and Davis (1975), Marholin and Phillips. (1976), 
Sprague and Baxley, (1978), Sprague and Werry, (1971), and Wysocki and Fuqua, 
(1982). In summary, more knowledge is required about the behavioral effects 
of even the more commonly used drugs with the mentally retarded. As yet, 
we cannot assume that the antipsychotics are beneficial to the majority of 
mentally retarded persons. 
REDUCTION OF DRUG USE 
Since antipsychotics are widely prescribed for the mentally retarded 
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and their effects and side-effects have not been adequately evaluated, a 
number of researchers have developed ways of reducing the dosage of anti-
psychotics when these are used as maintenance medication. 
Fielding, Murphy, Reaga~, and Peterson (1981) devised a two-phase 
assessment program, with the first phase involving alternating periods of 
medication and non-medication in an attempt to identify those individuals 
who could effectively participate in treatment without their prescribed 
medication. The second phase involved only those individuals who responded 
adversely during non-medication periods. In this phase, their doses were 
reduced gradually, until the minimum effective dose was reached. The 
occurrence of all maladaptive behaviors of each resident was monitor.ed for 
90 days. This drug assessment program was reported to be highly successful 
in terms of subject behavior, staff time, and cost effectiveness. However, 
no formal behavioral observations were undertaken and the responses of the 
clients could not be objectively assessed. 
Ferguson, Cullari, Davidson & Breuning (1982) employed an ABAB design 
to evaluate the use of data-based review with 250 mentally retarded 
residents. Dosages were typically reduced by 25% to 50% per 30-day period 
but only afte~ the residents' behavior had stabilized. Evaluations of the 
individual resident's behaviors were based on 24-hour frequ~ncy counts of 
inappropriate behaviors. The authors suggested that the program was 
successful in reducing the antipsychottc medication for ninety-seven percent 
of the subjects. Unfortunately, these findings are questionable since no 
observational data were reported. 
LaMendola, Zaharia, and Carver (1980) reported a study in which the 
subjects' antipsychotic medication was reduced to low levels. The subjects' 
behaviors were monitored and a team approach to drug reduction was employed., 
Again no formal behavioral observations were made and the results are 
difficult to interpret. Further, it is not clear how drug reduction 
decisions were made. 
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In a naturalistic study, Singh & Winton (in press) utilized behavioral 
observations to assess the effects of psychoactive drugs ·on the self-
injurious behavior of a mentally retarded boy. The effects of three drugs 
(carbamazepine, thioridazine and chlorpromazine) were assessed at several 
different dose levels. This study showed that medication was not effective 
in suppressing the behavior of the boy and, consequently all medication was 
withdrawn. It would seem that behavioral monitoring is a precise, 
objective and reliable method for assessing drug effects. Individual 
behavioral observations are useful for determining the efficacy of 
medication at various doses in the treatment of behavioral problems. Via 
this procedure, drug dosages can be increased or decreased to optimum levels. 
Drug Holidays: Another method of reducing drug dosages is via drug 
holidays. A drug holiday means that the resident is given a "holiday" from 
,his maintenance medication. Usually, a holiday of 4 to 6 weeks is 
prescribed. Thus a resident who is on a maintenance dose of an anti-
psychotic may have a 4 to 6 week drug free period at given intervals, 
usually once or twice each year. 
Heistad, Zimmerman and Doebler, (1982), discontinued the use of thior-
idazine by 106 mentally retarded residents for a period of four to five 
weeks. Prior to and during the drug withdrawal period, the subjects' 
behaviors were monitored via time-sampling. A significant increase in the 
rate of self-stimulation and active negative behavior was found. Work and 
life skills also decreased during the drug-free condition. In contrast to 
the majority of subjects, a few patients showed significant improvement 
during this phase. Patients whose behavior worsened most during the drug-
free phase made more favourable long-term progress once medication was 
restored. Unfortunately, on+y the mean data are presented and few details 
on individual responses are provided in this study. 
Marholin et al (1979) provided data on five subjects whose medication 
was withdrawn for a maximum of 23 days in any one period. Their results 
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showed that the residents' behavior was heavily influenced by chlor-
promazine withdrawal only in some cases and virtually unaffected in others. 
Some subjec.ts showed significant increases in undesirable behavior, while 
others made significant behavioral improvement. 
Intermittent Drug Therapy: As the name implies, patients who are on 
maintenance medication may have their medication on an int~rmittent basis. 
The usual method is to provide medication only on certain days of the week 
(e.g., Monday, Wednesday and Friday) or during certain months of the year 
(e.g., alternate months). Although there are no examples of intei;mittent 
drug therapy with the mentally retarded, the psychiatric literature con-
tains a small number of relevant studies. In the first study to employ 
intermittent drug therapy (Olson & Peterson, 1962), 90 chronic schizophrenics 
were randomly assigned to groups in which (1) chlorpromazine or thioridazine 
was administered daily for 6 months, (2) chlorpromazine or thioridazine was, 
administered daily for first, third and fifth months, with placebo for the 
other three months, or (3) chlorpromazine or thioridazine was administered 
da:ily for the first, third and fifth months and no medication was admin-
istered for the other three months. Relapse (regression requiring 
resumption of previous medication) occurred in 8% of the first group, 29% 
of the second, and 85% of the third group. 
In another study, Prien, Gillis and Caffey (1973) randomly assigned 
375 chronic schizophrenics to one of the following groups (1) daily 
schedule of normal medication, (2) prestudy dosages Monday to Friday, with 
placebo on Saturday and·Sunday, (3) placebo on Tuesday and Saturday, 
normal medication on the other five days, (4) prestudy dosages Monday to 
Thursday with placebo from Friday to Sunday, and (5) placebo Tuesday, 
Thursday and Saturday, with prestudy dosages on the other days. After 16 
weeks, relapse had occurred in 1% of daily schedule patients (Group 1), 
6% of Group 2, 8% of Group 3, 7% of Group 4, and 6% of Group 5. None of 
these percentages was significantly different from one another. Thus, 
this study suggests that short-term withdrawal can be advantageous for 
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patients and staff in institutional settings. 
In a double-blind study reported by Caffey, Diamond, Frank, 
Grassberger, Herman, Klett & Rothstein (1964), 348 chronic schizophrenics 
received either (1) antipsychotic medication daily, (2) antipsychotic 
medication on Monday, Wednesday and Friday with placebos on the other days, 
or (3) plac~bos on Monday, Wednesday and Friday with drug-free days in 
between. After 16 weeks, 5% of continuous treatment patients had relapsed, 
15% on intermittent medication had relapsed, and 45% on no medication had 
relapsed. While the.results appear favorable for intermittent medication, 
the authors noted that borderline patients may have only been tolerated 
since they were also involved in the study. 
Other investigations on intermittent drug therapy have also found that 
a large majority of subjects can tolerate low levels of medication without 
relapse, (e.g., Chien & DiMascio, 1971; Greenberg & Roth, 1966). The 
effects of weekend drug-free schedules for chronic schizophrenics have 
been evaluated in two studies, with both showing no significant difference 
between weekend-free. and control groups (Chien & DiMascio, 1971; Fireman 
& Tynes, 1967). 
In summary, current research suggests that intermittent drug therapy 
is a useful and effective way of reducing maintenance medication of psy-
chiatric patients. It is advantageous ethically, since it minimizes 
negative side effects ~f antipsychotics, and practically, because it saves 
institutional time and money. 
Since intermittent drug therapy has not yet been investigated with 
mentally retarded persons, and few reduction procedures have been assessed 
with this population, it was considered informative to try this technique 
with the mentally retarded. The present study, then, investigated the 
utility of intermittent drug therapy, a novel procedure for mentally 
retarded populations. 
In addition, this study attempted to answer a number of questions 
concerning the effects of antipsychotics on behavior of mentally retarded 
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subjects. The few studies conducted have had mixed results, some showing 
antipsychotics to be largely ineffective, others indicating lower dosages 
to be more effective than higher ones. The present study attempted to 
overcome previous methodological problems found by being well-controlled 
(multiple baseline across subjects design, formal behavioral observations, 
placebos, interobserver reliability, double-blind, follow-up period). 
Further., it assessed antipsychotic effects across a broad spectrum of 
behaviors, and with six subjects, unlike most previous studies. 
In general terms then, the present study aimed to maximize the 
effectiveness of antipsychotic medication, and to simultaneously minimize 
any adverse effects. This was considered useful in the light of the wide-
spread use of antipsychotics with the mentally retarded. 
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METHOD 
Subjects and Setting 
Six profoundly retarded young men participated in the study. All 
were residents of an institution for menta~ly retarded persons. These 
residents had been maintained on antipsychotics (for three to seven 
years) for the management of behavior problems that included stereotypy, 
self-injury, aggressive and destructive behavior. 
Further information about the participants is presented in Table 2. 
Informed consent was obtained from the residential authorities before the 
study was commenced, and the protocol for this study was approved by the 
Ethics Committee of the North Canterbury Hospital Board. 
Insert Table 2 about here 
The villa/ward in which this study was conducted housed 43 profoundly 
and severely retarded males. The residents spent most of their time in 
the dayroom which is a large, sparsely furnished room. A variety of 
recreational activities were encouraged by staff in the villa. Apart from 
these daily activities, the subjects were not involved in any treatment or 
training programs throughout the study. 
Response Definitions 
Ten categories of behavior were observed. These categories were form-
ulated prior to the study by observing the subjects for two weeks on a 
daily basis. The categories and their definitions are presented in Table 
2. A large number of behaviors, involving desirable and undesirable, were 
observed in an effort to derive as much information as possible about the 










Profoundly mentally retarded 
of unknown etiology 
Profoundly mentally retarded 
and right Hemaplegia due to 
cerebral palsy 
Profoundly mentally retarded 
due to maternal rubella 
Profoundly mentally retarded 
of unknown etiology 
Profoundly mentally retarded 
due to maternal rubella 
Profoundly mentally retarded 
of unknown etiology 
aon AAMD criteria (Grossman, 1977) 
b . . 1 Fairview anguage age 
· cFairview behavioral age 
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Age (Mths) Drug Mg/Day 
17.3 Veractil 150 
19.l Veractil 125 
11.6 Veractil 150 
20.2 Veractil 75 
17.6 Largactil 75 


















Insert Table 3 about here 
Data Collection and Reliability 
Four ·observers with some experience in behavioral observation 
procedures were given additional training prior to and throughout the 
experiment. Data were collected by one observer, randomly assigned on a 
daily basis. A second observer was also randomly assigned on 25% of the 
sessions during each phase for reliability checks. An interval-recording 
technique was used to collect data on a daily basis in an unstructured 
ward setting. All observations were scheduled between 9.am and 11.am, 
five days a week. No observations were scheduled in the weekends. Each 
observation session of 15 minutes was divided into 90 consecutive 10-
second intervals. The end of each 10-second interval was signalled through 
earplugs to the primary observer who recorded the behaviors observed in . . 
each interval. The same signal was used for the reliability observer, when 
present. 
Baseline observations were undertaken only when the interobserver 
agreement between randomly assigned observer-pairs was above 85% on the 
Weighted-Agreement (W-A) index (Harris & Lahey, 1978). The W-A index was 
used since it provides the most conservative agreement measure and appears 
to be the index of choice for behavioral drug studies (see Towns, Singh & 
Beale, in press). 
The W-A index was calculated using the following formula: 
W-A (S-I x U) + (U-I x S) 
where S-I is the Scored-Interval index, 
U-I is the Unscored-Interval index, 
U is (the proportion of intervals left unscored by the primary 
observer plus the proportion of intervals left unscored by the 
second observer) divided by 2, and 
Sis (the proportion of intervals scored by the primary observer 
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TABLE 3 

















Any violent or negative physical behavior directed at 
people or objects; e.g., biting, scratching, hitting 
or forceful pushing of others, and, hitting, throwing 
or slamming objects in the dayroom. 
Any repetitive manipulation of objects, e.g., spinning, 
rubbing, tapping, fiddling with objects. 
Any repetitive movements involving only body parts, 
e.g., body-rocking or swaying, repetitive hand, finger, 
limb or head movements, teeth grinding, masturbation. 
Repetitive or continuous vocal sounds without comm-
unicative intent, e.g., humming, inappropriate laughter, 
screaming without provocation, uttering meaningless 
syllable combinations. 
Placing inedible or non-nutritive objects in mouth, 
chewing and/or swallowing them, e.g., string, clothing, 
cigarette butts. 
Any positive prosocial behavior directed at staff or 
residents, e.g., touching, patting, hand-holding, eye 
contact, smiling, or friendly-sounding vocalization 
with communicative intent. 
Any deliberate action causing harm to resident's own 
body, e.g., hand-biting, head-banging, face-scratching. 
When a resident makes two or more steps in the same 
direction (for Craig, crawling on all fours is 
included in.this category). 
The manipulation of toys in an appropriate manner, 
e.g., throwing bail to another person, block-building. 
When the subject is not engaged in any specific 
activity but rather is motionless, asleep, staring 
into space of engaging in small non-repetitive move-
ments. 
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plus the proportion of intervals scored by the second observer) 
divided by 2. 
The S-I index was calculated by dividing the number of agreements on 
occurrence in each interval by the number of agreements on occurrence plus 
the number of disagreements. If both observers agreed that no occurrence 
had occurred in the session the index was scored as 100% agreement. The 
U-I index was calculated by dividing the number of agreements on nonoccurr-
ences in each interval by the number of agreements on nonoccurrence:o plus 
the number of disagreements. If both observers agreed that the behavior 
had occurred in every interval, the U-I index was scored as 100% agreements. 
The interobserver agreements summed across the six subjects were (with 
ranges in parentheses) : Aggressive/destructive - 94% (87%-99%), 
stereotypy (objects) - 98% (94%-100%), stereotypy (body) - 91% 
(87%-95%), vocal sound - 84% (76%-92%), pica - 100%, social interaction -
98% (95%-100%), self-injury - 97% (91%-100%), walking/skipping - 95% 
(87%-98%), toy play - 87% (79%-94%), and other behaviors - 89% (85%-91%). 
Where both observers agreed on total occurrence or total nonoccurrence of 
a behavior in a session, the W-A index was scored as 100%. Percentage 
agreements were calculated by multiplying all indices by 100. 
Experimental Design 
A multiple baseline across subjects design (Baer, Wolf & Risley, 1968) 
was used to explore the effects of intermittent drug therapy on the behavior 
of each subject. The study contained five experimental phases·: baseline,. 
reduction, intermittent drug therapy, open and maintenance. Table 4 
details the number of days spent by each subject in the different experi-
mental phases. 
This was a double-blind, placebo-controlled study. Before baseline 
observations were initiated, the subjects' medication was changed from 
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tablets to capsule form. Medication was given with meals, three times 
a day, for all subjects. Each resident received only one capsule at 
each meal throughout the study. During the intervention phases when 
intermittent drug therapy was in effect, placebo capsules were substituted 
for active medication capsules. The placebo capsules were individually 
prepared to taste, smell and look exactly like the active medication for 
each subject. Each dose was individually packaged and had the subject's 
name, date, and time of administration written on it. Double-blind 
conditions were maintained during the first three phases, and single-
blind conditions were maintained during the fourth phase. Placebos were 
withdrawn in the final phase during which the subjects received their 
regular medication (in tablet form) on four days and no medication on the 
other three days of each week. 
Insert Table 4 about here 
Four observers, blindtothe study's purpose and procedures, made 
daily recordings of the subjects' 'behavior. The experimenter, nursing 
staff, hospital physicians, and others in contact with the subjects and 
observers were also blind to the experimental conditions. The research 
supervisor alone knew the order of subject entry, duration,'and dosage 
level associated with each condition for all subjects. A sealed envelope 
containing this information was given to the subjects' physician and another 
was placed in the subjects' medical files. 
Phase 1 : Baseline. Throughout the baseline phase, all subjects 
received their usual drug and dosage as outlined in Table 1. For Hugh, 
Richard, Craig, Ian, Dennis and Kevin the baseline lasted 10, 15, 20, 
25, 30 and 35 days, respectively. 
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TABLE 4 
DAYS SPENT IN EXPERIMENTAL PHASES 
PHASES 
Subjects Baseline Reduction Intermittent Open Maintenance 
Hugh 10 15 30 15 104 
Richard 15 15 30 15 98 
Craig 20 15 30 15 93 
Ian 25 15 30 15 88 
Dennis 30 15 30 15 83 
Kevin 3'5 15 30 15 80 
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Phase 2 : Reduction. Following baseline, all subjects participated 
in the dose-reduction phase which lasted three weeks. During Week 1, all 
subjects ceased to receive active medication for one day of the week (i.e., 
Monday). Active medication was still administered on six days, with 
placebo on the seventh. During Week 2, active medication was replaced by 
placebo on two days (i.e., Monday and Wednesday). The subjects received 
their usual drugs on the other five days. During the third week, active 
medication was replaced by placebo on three days (i.e., Monday, Wednesday 
and Friday). Active medication was administered on the other four days. 
Phase 3,: Intermittent drug therapy. Following the reduction phase, 
the days on which the placebos were administered were changed to make the 
procedure more economical and practical from a nursing point of view. In 
the first week, the drug-free day on Friday was changed to Saturday and in 
the second week, the drug-free day on Monday was changed to Sunday. Thus, 
from Week 2 onwards all subjects received placebos on Sunday, Wednesday 
and Saturday and active medication on Monday, Tuesday, Thursday and Friday. 
They continued to receive the active medication in the same dosages as 
before the study. In effect, all subjects had their weekly medication 
levels reduced by three-sevenths. However the subjects, observers, and 
nursing staff members were unaware of these reductions. 
Phase 4 : Open Phase. In this phase, placebos continued to be 
administered as described above, but the nursing staff were informed that 
all subjects were on active medication only on four days .and on placebos 
on the other three days. They were not told on which days the subjects 
received the active medication. 
Phase 5 : Maintenance. This condition lasted a minimum of eighty 
days, and differed from the previous phase on only one point. No placebos 
were .administered on the three drug-free days. Thus, staff were fully 
aware of the days on which subjects did not .receive drugs. 
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RESULTS 
The daily rate of stereotyped behavior, both body and object across 
all experimental phases is presented in Figure 1. Only the stereotyped 
behaviors have been graphed because they occurred at a relatively stable 
rate during baseline and had the highest rate of occurrence. All other 
behaviors were usually episodic. The phase means of all behaviors 
observed across all subjects are presented in Table 5. 
Insert Figure 1 and Table 5 about here 
Intermittent Drug Therapy: Overall Behavioral Effects 
Aggressive/Destructive Behavior. Overall, there was little change 
in the subjects' aggressive/destructive behaviors throughout the study. 
Five of the six subjects' aggressive/destructive behavior remained at 
extremely low levels despite reductions in the weekly dosage of their 
maintenance medication. 
Stereotypy. A slight increase was observed in all but one subject's 
object stereotypy from baseline to maintenance conditions. However, some 
degree of inter-phase variability occurred. As far as body stereotypy 
was concerned, it decreased in three subjects and increased in the other 
three. Again much inter-phase variation occurred. 
Vocal Sound. Vocal sound generally altered little across phases. 
Only one subject's responses showed some increase. 
Pica. The mean rate of pica varied little and, in general, inter-
mittent drug therapy appeared to have only minor effects on this behavior. 
Social Interaction. Social interaction showed a slight, clinically 
insignificant reduction in rate from baseline to the maintenance phase. 
Self-injury. Self-injurious behavior showed little change, although 
one subject's response rate increased slightly.' 
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FIGURE CAPTION 
Figure 1. Percent occurrence of stereotyped behaviors (object and body) 
across all experimental conditions. For the reduction and intennittent 
phases, the small letters with arrows beside them indicate the days 
on which placebos were given each week. Where these letters finish, 
placebos continue to be administered as indicated by the last letters 
( i . e • , SWS) • 
Gaps in the data occur where the subject was asleep, sick or 
away from the hospital during the observation period. 
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PERCENT OCCURRENCE OF BEHAVIORS ACROSS EXPERIMENTAL CONDITIONS 
Stereotypy 
Experimental Aggressive/ Vocal Social Self Walking/ Toy 
Condition Destructive Object Body Sound Other Pica Interaction Injury Skipping Play 
1. HUGH 
Baseline 4. 7 53. 3 63. 6 19.l 8.3 0.1 o.o 0.1 11.6 o.o 
Reduction 1. 7 40. 5 87.8 11.5 1.8 0.9 0.6 o.5 5.1 0.1 
Intermittent Drug 0.5 29. 4 89. 9 8.9 1.9 o.o o.l o.o 1.8 o.o 
Therapy 
Open o. 5 50. 5 67. 5 13.5 2. 3 o.o 0.0 0.0 4. 9 1.4 
Maintenance 0.1 13 93.3 18.3 3.1 0.1 0.3 o.o 2 .1 0.4 
2, RICHARD 
Baseline o. 2 16.5 23.5 38.5 3. 7 8.5 7.9 5.3 74.1 4 .4 
Reduction o.o 19. 5 51.l 46.5 3. 7 4.9 11.5 9.5 43.9 13.4 
Intend ttent Drug 
0.2 24. 9 68. 7 37 1.4 24 .4 9. 2 7.2 41.l 1.9 
Therapy 
Open o. 5 31.1 49. 5 43 4. 3 13.9 8.6 5.4 57. 7 2.0 
Maintenance 0.2 22. 5 46.4 33 .1 7. 7 13.6 6.9 5. 0 51.4 2 .3 
3, CRAIG 
Baseline 0.0 0.1 97 .6 1.5 1.1 0.1 0.1 o.o 1.1 o.o 
Reduction o.o 7. 7 81.7 o.o 8.6 0.0 o.o o.o o.o 0.0 
Intermittent Drug 
o.o 4.9 81.7 0.1 
Therapy 
12.4 o.o o.o 0.4 o.o o.o 
Open 0.2 7. 3 92. 7 3. 7 1.4 0.0 o.o 0.1 2. 3 o.o 
Maintenance o.o 6. J 78. 6 13.6 12. 7 o.o 0.1 1.9 1. l 0.0 
4, IAN 
Baseline o.o 39. 5 50.8 2 .0 8.1 6.0 1.8 o.o 32. 2 o.o 
Reduction o.o 51 41.8 1.3 29. 2 0.5 2.1 o.o 19.5 o.l 
Intermittent Drug 0.0 75.1 69 0.8 1.8 2.1 0.4 37 .6 
Therapy 
o.o o.o 
Open 0.0 55. 3 53. 7 0.1 1.9 3. 8 o.o o.o 18. 7 o.o 
Maintenance o.o 63.8 63. 7 4:a 10.4 4.9 0.4 o.o 34.8 0.1 
5, DENNIS 
Baseline o.o 57 .6 98. 2 5. 3 0.3 o.o 0.3 0.3 1.5 o.o 




0.1 63.8 98 5 0.1 0.0 0.2 0.5 2.8 0.3 
Open o.o 66.3 95.9 8. 3 3. 7 o.o o.o o. 3 0.0 
Maintenance o.o 67. 5 94. 5 6. 5 1. 3 0.1 0.1 0.3 3.6 o.o 
6, KEVIN 
Baseline 0.0 9.2 86.3 o.o 7. 3 o.o o. 0 o.o 0.0 o. 0 
Reduction o.o 13 88.9 0.1 11.2 0.0 o.o 0.0 o.o > o.o 
Intermittent Drug o.o 11.4 96.1 0.6 3. 9 0.1 
Therapy 
o.o o.o o.o 3 .1 
Open 0.0 7. 3 89 0.4 9. 7 0.0 o.o o.o 0.0 o.o 
Maintenance o.o 10. 5 84 1.7 11. 7 o.o o.o 0.1 o.o o.o 
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Walking/Skipping. The rate of walking/skipping decreased in two 
subjects (Hugh, Richard) and remained'constant in the others (Craig, Dennis, 
Ian, Kevin) when baseline and maintenance phases were compared. 
Toy Play. Toy play responses varied little across all phases. 
Few behaviors showed marked changes when baseline rates were compared 
to the maintenance rates. The only trend noticeable in Figure 1 is the 
slight increase in object stereotypy of most subjects. No dramatic 
increases or decreases occurred in any behavior in any of the subjects. 
Overall, the reduction in the number of days of maintenance medication per 
week had little impact on the behaviors measured. 
Intermittent Drug Therapy: Behavioral Effects for Each Subject 
Hugh. Prior to this study, Hugh was well-known for his aggressive 
outbursts towards other people and objects. However, during the course of 
this study, his aggressive/destructive behavior decreased dramatically. 
Following the baseline phase, when Hugh's medication was reduced to 4 days 
a week, the frequency of his aggressive/destructive responses decreased by 
an average of 36 percent. During the intermittent drug therapy and open 
phases, the rate decreased further to about 11 percent of the baselin~. 
Finally, during the maintenance phase, his aggressive/destructive responses 
decreased on average to 2 percent of the baseline rate. 
Hugh's object stereotypy also decreased dramatically, from baseline 
to maintenance, however a large increase in such behavior occurred during 
the open phase. No such increases were apparent in other behaviors during 
this phase. Body stereotypy increased substantially from baseline to the 
maintenance phase, with a large reduction occurring in the open phase. 
If these two categories of stereotyped behaviors are taken together, then 
there is a minor decrease across phases in Hugh's rate of stereotypy. 
His rate of total stereotypy decreased in the maintenance phase to 91 
percent of the baseline rate. 
Hugh's rate of vocalizing varied little across the five conditions, 
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although some reduction occurred during the intermittent drug phase. 
Pica and self-injury remained at very low levels throughout the study, 
although both increased marginally during the reduction phase before 
returning to baseline levels in the other phases. Social interaction 
and toy play occurred at very low rate~ throughout the study. Finally, 
walking/skipping gradually decreased across conditions. 
Richard. The mean rate of Richard's aggressive/destructive behavior 
remained stable and very low throughout the five phases. 
Object stereotypy increased systematically from baseline through 
reduction, intermittent drug therapy and open phases, and decreased in 
the maintenance phase to near-baseline level. In terms of body stereotypy, 
there was a near-doubling of the mean rate from 24% in baseline to 46% 
in the maintenance phase. Body stereotypy was highest in the intermittent 
drug phase. Thus, the mean rate of total stereotypy increased markedly. 
After an initial increase in the reduction ~hase, vocalization decreased 
gradually to lower than the baseline level in the final phase. However, 
this reduction was not clinically significant. The mean rate of pica 
dropped in the reduction phase by 58% when compared to the baseline, but 
increased in the maintenance phase to 160% of the baseline. 
Richard's frequency of social interaction was higher than baseline 
levels in the reduction, intermittent drug therapy and open phases, but 
dropped to slightly lower than baseline level in the maintenance phase. 
Similarly, self-injurious responses decreased by only 6% when baseline and 
maintenance phases were compared. Reduction and intermittent drug phases 
showed a slight increase in rate of such responses though. Walking/ 
skipping responses decreased for all phases following baseline. Finally, 
toy play increased substantially from baseline to the reduction phase, but 
decreased subsequently to lower than baseline levels in the last three 
phases. 
Craig. Craig's aggressive/destructive behavior was minimal through-
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out the study, with the highest rate occurring in the open phase. Social 
interaction and toy play were also at a low rate and indicated no or 
little change across conditions. 
Results of the two fonns of stereotypy were opposite, with object 
stereotypy increasing across phases, while body stereotypy decreased 
across conditions. However, body stereotypy was still emitted at a high 
level. Craig's vocalization also reached higher levels in the maintenance 
phase when compared to pre-maintenance conditions. Pica remained at 
zero levels following the baseline phase. The mean rate of self-injurious 
responses increased slightly across treatment phases. Craig's walking/ 
skipping showed no change when baseline and maintenance phases were compared 
although there were minor changes in rate during the three middle conditions. 
Overall change across categories such as aggressive/destructive, pica~ 
social interaction, skipping/walking and toy play were minimal. 
Ian. Overall,Ian's behavior varied little across the different treat-
ment phases. Two undesirable behaviors, aggressive/destructive and self-
injury, remained at zero for all treatment phases. 
The two types of stereotypy increased somewhat from baseline to the 
maintenance phase. Object stereotypy was higher in all phases following 
baseline, but peaked 'in the intennittent drug therapy condition where it 
was almost twice the baseline rate. Body stereotypy increased less markedly 
from baseline to the maintenance phase but also reached its peak during 
the intermittent drug phase. The mean rate of vocal sound, walking/ 
skipping and toy play responses increased minimally from baseline to the 
maintenance phase. The rate of walking/skipping was lower than baseline 
in the reduction and open phases but was slightly higher than baseline in 
the intennittent drug phase and the final treatment phase. Pica decreased 
substantially from baseline to the reduction phase and then slowly in-
creased in the next 3 phases, although remaining lower than the baseline 
level., Soci~l interaction also decreased slightly from baseline to the 
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maintenance phase, despite an initial increase during the reduction phase. 
Dennis. Dennis' aggressive/destructive behavior remained at zero or 
near-zero level across all conditions. Object stereotypy increased some-
what from baseline to the maintenance phase, with its highest rate occurring 
in the reduction phase. Body stereotypy, however, was lowest duri_ng the 
reduction phase, decreasing slightly overall from baseline to the maint-
enance phase. The mean rate of vocal sound and walking/skipping increased 
slightly from baseline to the maintenance phase, although both behaviors 
were lower than baseline during the reduction phase. Pica and self-injury 
varied little across conditions. Social interaction and toy play also 
varied little across the five phases. Thus, only object stereotypy changed 
noticeably from baseline to the maintenance phase. 
Kevin. Kevin's behavior showed no clinically significant changes 
from baseline to the maintenance phase. For three undesirable behaviors, 
aggressive/destructive, pica and self-injury, little or no change occurred 
throughout the study. 
Stereotypy also showed minimal change across conditions. Object 
stereotypy increased slightly in all post-baseline phases except in the 
open phase. However, body stereotypy showed a minor decrease when baseline 
and the maintenance phases were compared. All three middle phases had 
response rates higher than baseline. The three desirable behaviors, social 
interaction, walking/skipping and toy play also showed little or no change 
across all phases. Finally the frequency of vocalizations increased 
slightly from baseline to the maintenance phase, with all four post-baseline 
phases exceeding the baseline rate. 
Statistical Analyses 
To complement a visual analysis, a series of statistical analyses 
appropriate for N=l designs were carried out (see Kazdin, 1982). A para-
metric test could not be used because some if its assumptions were violated 
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(e.g., homogeneity). Instead, the nonparametric randomization test was 
used. The first eight data points of the baseline and the last eight data 
points of the maintenance phase were compared. For this test, object and 
body stereotypy were combined. No differences were found, except on five 
occasions. Hugh wa~ked/skipped less in the maintenance phase when compared 
to the baseline. For Richard, the reduction in drug dosage appeared to 
result in an increase in total stereotypy and an increase in frequency of 
pica. Richard also engaged in less walking/skipping and less toy play 
after drug withdrawal. Thus, only two undesirable behaviors increased 
during the maintenance phase. All other undesirable behaviors (i.e., 
twenty-two in total) showed no change when baseline and maintenance phases 
were compared. It should be noted that a few categories (e.g., Craig's 
vocal -sound) could--not be tested -with this method, due to the episodic 
nature of the behaviors. 
The statistical analyses confirm the visual analyses in that the 
subjects' behaviors did not show any systematic change due to a change in 
their medication schedule. Although statistical_analyses are not 
obligatory in studies of this nature, these were performed because of the 
variability of some of the behaviors of the subjects. In such cases, it 
has been suggested that statistical analyses may increase the strength of 
the data (see Kazdin, 1982). 
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DISCUSSION 
The present study investigated the effects of substantially reduced 
antipsychotic medication for a group of mentally retarded persons. Two 
areas were studied, namely, the effects of antipsychotics on a wide range 
of subject behaviors, and, the utility of a novel drug-reduction procedure 
with the mentally retarded. 
The results are not clearcut due to the multitude of variables 
assessed (i.e., observations were made on ten behaviors for each subject 
across five experimental phases). The data are also highly individual-
istic and difficult to summarize statistically. Nevertheless, a general 
trend of no clinically significant difference in subject behavior from 
baseline to maintenance phases is noticeable. When subjects are considered 
individually, and changes in their desirable behaviors are weighed 
against changes in their undesirable behaviors, the results are positive 
for all subjects. Negative changes were minor and were outweighed by far 
by changes in the positive direction. No subject had an increase in 
either aggressive/destructive or total stereotyped behavior from baseline 
to maintenance phases. This is a highly significant finding, given that 
these two classes of behavior appear to be the most common reason for the 
prescription of antipsychotic medicatio~. It is interesting that all 
subjects in this study were first prescribed veractil or largactil for 
an aggressive outburst or stereotyped behavior. 
It appears from the above finding, that these subjects were receiving 
inappropriately high dosages of antipsychotics to control their behavior 
problems. It is unfortunate that as a general rule, medication is not 
periodically withdrawn or given on an intermittent basis and behavioral 
data collected on the.effects of this regimen. This might ensure that 
residents are not kept on unnecessarily high dosages. Relevant to this 
finding is the suggestion that the original reason for medication may 
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have long ceased to operate for a resident, and hence medication may no 
longer be necessary (Lipman, 1982). Furthermore, with some residents, 
adverse side-effects may develop as a result of maintenance medication. 
In the present study, the overall results were the same for the 
child on the highest dosage (i.e., Richard) and the child on the lowest 
dosage (i.e., Ian) prior to the intervention. Regardless of their 
dosage level, subjects consistently exhibited little change across 
behaviors from baseline to maintenance phases. Unlike most studies on 
the effects of antipsychotics, the present study investigat.ed the effects 
of a range of individual dosages. Thus the findings of no change for all 
subjects may be realistically generalized to the broader population of 
mentally retarded persons. 
Lipman (1982) stated that studies involving drug-withdrawal conditions 
represent tests of the need to maintain residents on medication. The 
present study compared high versus lower weekly dosage levels. For all 
subjects involved, the lower weekly dosage resulted in similar. or better 
behavior than the higher dosage. The dosages these subjects were 
receiving prior to intervention need not have been as high. Despite the 
small subject sample, it could be ~rgued from these results that lowered 
dosages would prove beneficial for other institutionalized mentally retarded 
individuals. One would predict that no clinically significant behavioral 
changes would occur, and the negative side-effects associated with higher 
dosages of antipsychotics would be lessened considerably. 
It would seem from the-results of this study that veractil and 
largactil are similar in terms of their general action. No clinically 
significant differences were found between subjects on veractil and 
subjects receiving largactil. 
The results of this study can be discussed with respect to other 
relevant investigations. However, it should be noted that such 
comparisons are hindered by the great discrepancy between the studies' 
methodologies. Unlike many of the early chlorpromazine studies, (see 
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reviews by Freeman, 1970; Lipman, DiMascio, Reatig & Kirson, 1978; 
Sprague & Werry, 1971), the present study did not find medium to high 
dosages of chlorpromazine to effectively reduce the maladaptive behavior 
of mentally retarded people. The frequency of stereotyped behavior was 
very high for most subjects on maintenance dosages. Also, lower dosages 
of the same agent were found to be as beneficial as higher dosages. A 
recent, well-controlled study reported much variation in individual 
responses to chlorpromazine (Marholin et al., 1979). Marholin et al. 
reported that while results varied from subject to subject, the general 
trend was an increase in desirable subject behavior when chlorpromazine 
was discontinued. Furthermore, the abrupt drug withdrawal and short 
placebo phase may have biassed the above study against positive results 
since withdrawal emergent symptoms (e.g., withdrawal dyskinesias) may 
not have had time to subside. Thus, the above investigation and the 
present study both found the prescribed chlorpromazine medication of 
mentally retarded subjects to be excessive, and decreased dosages to be 
more beneficial. 
While Lipman (1982) has stated that chlorpromazine is capable of 
reducing stereotyped movements and suppressing aggressive and self~ 
destructive behaviors, he cites no studies in his review which support 
his contention. In fact, no well-controlled investigations could be 
found which have shown chlorpromazine to suppress stereotyped and 
aggressive behavior. The present study also provides little support 
for chlorpromazine's beneficial effects. 
Several methodologically sound studies 'have been conducted with 
antipsychotics other than chlorpromazine. In a drug-withdrawal study 
(Singh & Aman, 1981), a low and a high dosage of thioridazine were 
compared using twenty mentally retarded subjects. The low dosage was 
found to be just as effective in suppressing stereotyped behavior as the 
higher dosage. The present study, then, reports findings consistent 
with the above study, although methodologically the two studies are 
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somewhat different. 
Heistad, Zimmerman and Doebler (1982) investigated the effects of 
thioridazine discontinuation and found that some mentally retarded 
subjects improved significantly when medication was temporarily with-
drawn. However, an increase in stereotypy and active negative behavior, 
as well as decreased life and work skills occurred in other subjects. 
These results provide mixed support for the present investigation. 
Other investigations on thioridazine have reported data more consistent 
with the present study. Davis (1971), for example, reported no 
significant changes in the behavior of two subjects during thioridazine 
and placebo conditions. Finally, Breuning (1982) showed that different 
dosages of thioridazine were optimal in reducing different inappropriate 
behaviors in patients known to be drug-responders. For non-responders, 
the frequency of inappropriate behaviors increased as thioridazine 
increased. The present study also indicated that drug withdrawal may 
have different effects on different subjects. However, the general 
finding of no significant behavioral change during intermittent drug 
therapy suggests that other mentally retarded persons might benefit from 
lower dosages· of maintenance medication. 
The present study, unlike most other drug investigations, provides 
strong support for attempts to lower the maintenance medication of the 
mentally retarded. The present findings can be cited as evidence to 
institutional staff that periodic reductions in medication levels may be 
beneficial to institutionalized mentally retarded persons. •This is an 
important finding particularly in view of the number of negative side-
effects of antipsychotic medication. For instance, a number of 
investigators (Breuning, Davis, Matson & Ferguson, 1982; Paulson, Rizvi 
& Crane, 1975; Kumar, 1976) have found tardive dyskinesia to be a 
problem, particularly when antipsychotic dosages are high and/or 
prescribed for long periods of time. Further, current research suggests 
that high dosages of antipsychotics may impair learning performance of 
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mentally retarded persons (Breuning & Davidson, 1981; Breuning, Ferguson, 
Davidson & Poling, in press; Wysocki, Fuqua, Davis & Breuning, 1981). It 
is crucial then, that levels of maintenance medication are kept to a 
minimum. 
The results of this study are also interesting since they provide 
more knowledge on the type of strategy that may be useful in achieving 
minimum dosage levels. The present study evaluates the utility of 
intermittent drug therapy in the context of a number of conditions (i.e., 
gradual drug reduction, intermittent drug therapy, open and maintenance 
conditions). This is the first study in the area of pharmacotherapy 
with the mentally retarded to use and evaluate such a procedure. 
At present, no comparative data are available on methods of regulating 
drug prescription with regards to efficacy and long-term benefits for 
mentally retarded persons. While the inherent differences between the 
present study and other drug reduction studies are recognised, a comparison 
of the results is considered useful. The Fielding et al. (1980) study 
involved a phase of gradual drug reduction (dosages reduced by 25% or 
100mg after each 30-day period of appropriate subject reaction) similar 
to the reduction phase ?f the present investigation. Likewise, they 
reported that the majority of subjects benefitted ~ram reduced dosages! 
in that their maladaptive behaviors did not significantly worsen. How-
ever, Fielding et al.'s initial period of non-med~cation may have resulted 
in some unpleasant withdrawal-related side-effects for the subjects. 
·In a study similar to that of Fielding et al., but with more gradual 
drug withdrawal for all subjects, Ferguson et al. (1982) reported that 97 
percent of their subjects had either discontinued or decreased maintenance 
medication without significant deterioration. While these results were 
consistent with those of the present study, formal behavioral observations 
were an added advantage of the latter. 
LaMendola et al. (·1980) also reported the benefits of reduced and 
discontinued medication, similar to the present study. Unfortunately, 
LaMendola et al.'s drug assessment was not derived from data-based 
behavioral observations. 
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Heistad et al.'s (1982) investigation reported findings contrary to 
those of the present study, since the majority of their subjects 
exhibited more negative behaviors during the placebo condition. How-
ever the negative results could have represented in part, negative side-
effects of abrupt drug withdrawal (see Gualtieri & Hawk, 1980). Further, 
it should be noted that such drug holiday studies differ considerably 
from studies using intermittent drug therapy, as in the present invest-
igation. This may be one reason why results are often dissimilar. 
Most of the research in the area of intermittent drug therapy has 
shown that the majority of subjects can tolerate low dosages without 
relapse. Also consistent with the present study was Caffey et al's 
(1964) study with schizophrenics where only fifteen percent of those 
receiving antipsychotic medication three days a week relapsed, compared 
to five percent on continuous medication. Perhaps the study most 
r.elevant to the present investigation was by Prien et al. (1973) in which 
a large group of schizophrenics received one of five different conditions. 
The results showed a relapse rate of six to eight percept for the four 
intermittent drug therapy groups (i.e., no antipsychotic.medication for 
two, three or four days a week) compared to one percent in the full 
medication group. While.the Prien et al. (1973) study represents a 
relatively well-controlled investigation, once again formal observational 
recording was not employed. 
It is unfortunate that the few studies relevant to the present 
investigation usually lacked methodological rigor. A common flaw was 
the use of informal evaluations to assess the global effects of drugs. 
Admittedly drug evaluation studies dealing with large numbers of subjects 
and using daily behavioral observations can be extremely time consuming 
and costly to conduct. Perhaps researchers interested in large subject 
groups and their reactions to drug withdrawal should randomly select a 
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small sample of these subjects for behavioral observation as well. 
Many of the studies investigating specific methods of drug 
reduction are also methodologically deficient. Some studies failed to 
use double-blind controls or paid little attention to extraneous 
variables related to abrupt drug withdrawal. The present investigation 
should be helpful to those researchers who are interested in developing 
and refining drug-reduction and drug-withdrawal procedures. 
The present study represents a relatively novel way of reducing 
dosage levels and evaluating on a daily basis, the client's reaction to 
drug withdrawal. Gradual withdrawal of antipsychotic medication, as in 
this study, facilitates the subject's adjustment to l_ower dosage levels 
and reduces the likelihood of the occurrence of drug withdrawal emergent 
symptoms. Other advantages are the double-blind aspect of this study, 
formal behavioral observations on a daily basis for eight months, the 
use of a robust interobserver reliabiiity index, and the use of the 
multiple baseline design. The long duration of the study meant that drug 
effects and subject reactions to intermittent drug therapy could be 
assessed over a long time period. Further, any drug withdrawal effects 
had ·sufficient time to subside. Formal observations were made across a 
broad spectrum of behaviors, including stereotypy and self-injury, two 
behaviors frequently exhibited by the mentally retarded but about which 
little is currently known with respect to drug therapy. 
An additional benefit with intermittent drug therapy is its ease of 
implementation. Once established, the·Friday and weekends off procedure 
is easily maintained in the institutional setting where fewer staff are 
employed in the weekends. This study.then, investigated a technique 
which is a practical and viable alternative to daily maintenance medication in 
the institutional setting. It is also advantageous in that it consider-
ably reduces expenditure related to pharmacological agents. Moreover, the 
the benefits are obvious in terms of sav1ngs in staff time usually spent 
in the preparation and administration of drugs. 
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The present study has a number of merits. Firstly, it improved on 
previous research in the area. A number of researchers have emphasized 
the need for well-controlled efficacy studies with the antipsychotics 
(e.g., Aman, 1983; Aman & Singh, 1980; Lipman, 1982). Specifically it 
has been suggested that the effects of different dosages be explored, 
that efficacy studies last longer than three to six months, that a range 
of behaviors, both adaptive and maladaptive be observed, and that 
adequate research designs be employed. This study, then, has contributed 
directly to the area of drug efficacy ~nd dosage-related research. 
Moreover, the present results challenge the common assumption that raising 
the dosage will result in greater and more beneficial effects. In fact, 
it would seem from the current research that antipsychotics (and perhaps 
psychotropic drugs in general) do not act in a linear fashion. Rather, 
as Aman (1983) has suggested, it is likely that quite different dose-
response relationships will be found between optimal social functioning 
versus optimal cognitive functioning. 
Of major concern currently is the. question of which dosage level is 
safest for the mentally retarded, and still effective. For a number of 
ethical and practical reasons it is important that researchers determine 
the lowest, most therapeutic level of medication for the mentally retarded. 
Retarded persons are passive recipients of pharmacological agents, and 
must often endure the adverse effects a~sociated with drug therapy, 
including potential cognitive learning impairment, negative physiological 
effects. and extrapyramidal side-effects. Given that antipsychotics are 
still the most popular choice of medication for the mentally retarded, 
studies such as the present one contribute to the determination of the 
optimal dosage level of these drugs. 
Although the generality of the present findings needs to be 
established through replication, this study does suggest that discontinuing 
antipsychotic maintenance medication for three days per week is a safe, 
viable, easily implemented, cost-effective, and potentially valuable 
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